Skip to content

Menu

LexBlog, Inc. logo
CommunitySub-MenuPublishersChannelsProductsSub-MenuBlog ProBlog PlusBlog PremierMicrositeSyndication PortalsAboutContactResourcesSubscribeSupport
Join
Search
Close

The Race for a COVID-19 Vaccine is On: Key Factors May Impact Patent Protection

shutterstock_1035322879
By Chinh H. Pham on May 26, 2020
Email this postTweet this postLike this postShare this post on LinkedIn

The search for a vaccine for the COVID-19 strain of coronavirus has put the spotlight once again on the innovative pharmaceuticals sector.  As pharmaceutical companies and innovators across the globe work diligently on a vaccine, many of these companies may be looking to protect their innovation. While patents have many benefits, in the face of a global health emergency, there are some key factors innovators should consider.

Timeline for Patent Registration

Patents can provide broad protection for invention and innovation.  They can also create a significant advantage in the marketplace. However, patent registration takes time and may require significant resources. According to the United States Patent and Trademark Office (USPTO), on average, it takes approximately 22 months to get patent approval.  This period may be shortened by taking advantage of one of the USPTO’s accelerated examination procedures and may be shortened by utilizing the USPTO prioritized examination option, where a final decision on patentability is made within 12 months from the filing date of the patent application.

For a potential COVID-19 vaccine being developed now, the USPTO recently announced a new pilot program, where the USPTO will waive typical fees associated with prioritized examination to applicants who qualify for small or micro entity status.  In addition, the USPTO will endeavor to reach a final decision on the applications in this pilot program within six months.

A shorter period to a patent decision may cut down on the costs to a company and allow the company to enjoy the benefits of exclusivity that come with a patent.  However, such exclusivity may be short-lived, especially in the presence of an ongoing pandemic.

Compulsory Licenses

In time of crisis, the U.S. government may force patent owners to grant compulsory licenses when there is a threat to public safety.  A compulsory license refers to the government’s authority to grant permission to a party seeking use of a patent owner’s invention without the consent of the patent owner and is provided broadly by 28 U.S.C. § 1498 (“Section 1498).

Under Section 1498, the U.S. government has the “right to use patented inventions without permission, while paying the patent holder ‘reasonable and entire compensation.’”  The statute also “allows federal agencies and third-party government contractors to manufacture and/or use any invention without authorization from the patent holder.” The U.S. government has invoked or threatened to invoke this right in the past when faced with a national health emergency.

For example, with anthrax in the early 2000s, apharmaceutical company holding the patent for an anthrax antidote was faced with the possibility of Section 1498 being invoked by the US Secretary of Health and Human Services. The pharmaceutical company ultimately responded by supplying the anthrax antidote to the public at a 50% discount.

March-In Rights

March-in rights, a provision of the Bayh-Dole Act of 1980 and is codified in 35 U.S.C. § 203, may also be invoked if there is a threat to public safety. March-in rights allow the federal government the right to grant patent licenses to other parties or take licenses for themselves, if the patented invention was researched and developed with the help of federally funded dollars.

No U.S. federal agency has exercised its power to march-in and grant a license to the patent rights.  Nevertheless, the possibility of march-in rights being invoked needs to be considered should a company contemplates receiving government funding for research and development of a drug or vaccine that may someday provide a significant benefit to the public.

Caveat

Innovators have always been creative in employing a variety of approaches to protect their intellectual property. But when faced with a global health crisis and the immediate need for public access to patented inventions, innovators should be mindful when exploring patent protection, as their exclusive rights in the patented invention may be superseded by the greater need of the public.

Take steps to assure you understand the measures available to the U.S. government before investing significant resources or taking on government funding in developing your next drug or vaccine.

Photo of Chinh H. Pham Chinh H. Pham

Chinh H. Pham is Co-Chair of the Emerging Technology Practice and is a registered patent attorney with experience in the strategic creation, implementation and protection of intellectual property rights for high technology and life science clients.

Chinh advises clients, ranging from start-ups to

…

Chinh H. Pham is Co-Chair of the Emerging Technology Practice and is a registered patent attorney with experience in the strategic creation, implementation and protection of intellectual property rights for high technology and life science clients.

Chinh advises clients, ranging from start-ups to established companies, on the creation and development of patent portfolios through the preparation and filing of patent applications, the acquisition and exploitation of intellectual property rights through licensing and strategic collaboration agreements, and the preparation of invalidity, non-infringement, and freedom-to-operate opinions. Chinh also counsels clients on IP due diligence through the evaluation of client and competitor portfolios.

Chinh assists startup clients with strategies for leveraging their IP portfolio for high-value commercial opportunities, introducing them to funding sources, either through the venture community or the government, as well as identifying and establishing strategic alliances.

Read more about Chinh H. PhamEmail
Show more Show less
  • Posted in:
    Corporate & Commercial
  • Blog:
    Emerging Technology Views
  • Organization:
    Greenberg Traurig, LLP
  • Article: View Original Source

LexBlog, Inc. logo
Facebook LinkedIn Twitter RSS
Real Lawyers
99 Park Row
  • About LexBlog
  • Careers
  • Press
  • Contact LexBlog
  • Privacy Policy
  • Editorial Policy
  • Disclaimer
  • Terms of Service
  • RSS Terms of Service
  • Products
  • Blog Pro
  • Blog Plus
  • Blog Premier
  • Microsite
  • Syndication Portals
  • LexBlog Community
  • 1-800-913-0988
  • Submit a Request
  • Support Center
  • System Status
  • Resource Center

New to the Network

  • Boston ERISA & Insurance Litigation Blog
  • Stridon News and Insights
  • Taft Class Action & Consumer Insights
  • Labor and Employment Law Insights
  • Age of Disruption
Copyright © 2022, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo